Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBS-001 vs Eylea in Neovascular Age-Related Macular Degeneration
2023-509206-29-00Phase 3Completed
- Sponsor
- Rophibio
- Start
- May 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of RBS-001 in exudative macular degeneration (2 arms), sponsored by Rophibio. Primary endpoint: Change in best-corrected visual acuity at week 8. Started May 2024; status: completed.
02
Drugs
RBS-001
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2023-509206-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509206-29-00.